Etelcalcetide Hydrochloride (BioDeep_00000839936)
代谢物信息卡片
Etelcalcetide Hydrochloride
化学式: C38H74ClN21O10S2 (1083.5057213999999)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C.Cl
InChI: InChI=1S/C38H73N21O10S2.ClH/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Katharina Dörr, Alexander Kainz, Rainer Oberbauer. Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease.
Current opinion in nephrology and hypertension.
2022 07; 31(4):339-343. doi:
10.1097/mnh.0000000000000799. [PMID: 35703173] - Hironori Nakamura, Masanori Tokumoto, Mariko Anayama, Shigekazu Kurihara, Yasushi Makino, Katsuhiko Tamura, Masaki Nagasawa. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
CEN case reports.
2022 05; 11(2):254-258. doi:
10.1007/s13730-021-00664-0. [PMID: 34787825] - Elizabeth A Swallow, Corinne E Metzger, Christopher L Newman, Neal X Chen, Sharon M Moe, Matthew R Allen. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Bone.
2022 04; 157(?):116340. doi:
10.1016/j.bone.2022.116340. [PMID: 35085840] - Angelo Karaboyas, Daniel Muenz, Douglas S Fuller, Pooja Desai, Tzu-Chieh Lin, Bruce M Robinson, Sandro Rossetti, Ronald L Pisoni. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2022 Mar; 79(3):362-373. doi:
10.1053/j.ajkd.2021.05.020. [PMID: 34273436] - William G Goodman, Donald T Ward, Kevin J Martin, Debra Drayer, Carol Moore, Jiahong Xu, James Lai, Yun Chon, Edward F Nemeth. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Journal of the American Society of Nephrology : JASN.
2022 01; 33(1):201-212. doi:
10.1681/asn.2021060825. [PMID: 34732508] - Changying Xing, Jing Chen, Li Zuo, Yi Fang, Xiaoqiang Ding, Zhaohui Ni, Carol Kong, Guiling Shi, Hong Lu, Jennifer Hellawell, Sunfa Cheng, Winnie Sohn. A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis.
Clinical therapeutics.
2021 11; 43(11):2013-2023. doi:
10.1016/j.clinthera.2021.09.019. [PMID: 34774334] - Tetsuo Shoji, Shinya Nakatani, Daijiro Kabata, Katsuhito Mori, Ayumi Shintani, Hisako Yoshida, Kanae Takahashi, Keiko Ota, Hisako Fujii, Shinichiro Ueda, Shinichi Nishi, Tatsuya Nakatani, Minoru Yoshiyama, Kiyoshi Goto, Takayoshi Hamada, Masahito Imanishi, Eiji Ishimura, Sosuke Kagitani, Yoshikazu Kato, Yasuro Kumeda, Kiyoshi Maekawa, Takayasu Matsumura, Harumi Nagayama, Yasue Obi, Yoshiteru Ohno, Yoshinori Sai, Mayumi Sakurai, Satoshi Sasaki, Kaori Shidara, Shigeichi Shoji, Yoshihiro Tsujimoto, Kenjiro Yamakawa, Hideaki Yasuda, Shozo Yodoi, Masaaki Inaba, Masanori Emoto. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2021 04; 16(4):599-612. doi:
10.2215/cjn.16601020. [PMID: 33685864] - Keitaro Yokoyama, Masafumi Fukagawa, Takashi Shigematsu, Takashi Akiba, Ken Yoshikawa, Akira Tsuchiya, Misato Kuwabara, Tadao Akizawa. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
Clinical and experimental nephrology.
2021 Jan; 25(1):66-79. doi:
10.1007/s10157-020-01936-2. [PMID: 32816132] - Winnie Sohn, Isidro B Salusky, Claus Peter Schmitt, Christina Taylan, Johan Vande Walle, Jude Ngang, Lucy Yan, Mark Kroenke, Bradley A Warady. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
Pediatric nephrology (Berlin, Germany).
2021 01; 36(1):133-142. doi:
10.1007/s00467-020-04599-z. [PMID: 32647975] - Carlo Massimetti, Marco Tondo, Sandro Feriozzi. [Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2020 Oct; 37(5):. doi:
. [PMID: 33026204] - David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt, Kevin J Martin, Anjay Rastogi, Pablo Ureña-Torres, Marc Vervloet, Geoffrey A Block. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2020 10; 35(10):1769-1778. doi:
10.1093/ndt/gfz039. [PMID: 30859218] - Yan Zhu, Jihong Ou, Xinkuo Liu, Zhijuan Xie. Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials.
Clinical nephrology.
2020 Oct; 94(4):173-180. doi:
10.5414/cn110110. [PMID: 32729818] - Suetonia C Palmer, Dimitris Mavridis, David W Johnson, Marcello Tonelli, Marinella Ruospo, Giovanni F M Strippoli. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2020 09; 76(3):321-330. doi:
10.1053/j.ajkd.2020.02.439. [PMID: 32475604] - Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama, Takashi Akiba, Akifumi Fujii, Atsushi Shinoda, Tadao Akizawa. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
Nephrology (Carlton, Vic.).
2020 Aug; 25(8):634-643. doi:
10.1111/nep.13682. [PMID: 31765028] - Antonio Bellasi, Mario Cozzolino, Fabio Malberti, Giovanni Cancarini, Ciro Esposito, Carlo Maria Guastoni, Patrizia Ondei, Giuseppe Pontoriero, Ugo Teatini, Giuseppe Vezzoli, Marzia Pasquali, Piergiorgio Messa, Francesco Locatelli. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.
Journal of nephrology.
2020 04; 33(2):211-221. doi:
10.1007/s40620-019-00677-0. [PMID: 31853791] - Mark D Danese, Deborah Lubeck, Vasily Belozeroff, Tzu-Chieh Lin, Pooja Desai, Michelle Gleeson, Kevin Martin, Michel Chonchol. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
American journal of nephrology.
2020; 51(10):815-822. doi:
10.1159/000510360. [PMID: 32966995] - Hannelore Sprenger-Mähr, Emanuel Zitt, Andreas Kronbichler, Manfred Cejna, Karl Lhotta. A hemodialysis patient with bone disease after pregnancy: a case report.
BMC nephrology.
2019 11; 20(1):425. doi:
10.1186/s12882-019-1603-8. [PMID: 31752733] - Katharina Dörr, Michael Kammer, Roman Reindl-Schwaighofer, Matthias Lorenz, Christian Loewe, Rodrig Marculescu, Reinhold Erben, Rainer Oberbauer. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
Trials.
2019 Oct; 20(1):601. doi:
10.1186/s13063-019-3707-7. [PMID: 31651370] - M W Aref, E A Swallow, C E Metzger, N Chen, S M Moe, M R Allen. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2019 Aug; 30(8):1693-1698. doi:
10.1007/s00198-019-04974-z. [PMID: 31069439] - Debra Hain, Holly Tomlin, Cristian Gibson. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective.
Nephrology nursing journal : journal of the American Nephrology Nurses' Association.
2019 May; 46(3):315-290. doi:
NULL. [PMID: 31199098] - Eugene Lin, Suzanne Watnick. Calcimimetics and Bundled Reimbursement.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2019 03; 73(3):385-390. doi:
10.1053/j.ajkd.2018.11.007. [PMID: 30611600] - Kazutsune Harada, Aiko Fujioka, Masakazu Konno, Atsuto Inoue, Hiroyuki Yamada, Yasushi Hirota. Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients.
European journal of pharmacology.
2019 Jan; 842(?):139-145. doi:
10.1016/j.ejphar.2018.10.021. [PMID: 30342948] - Geoffrey A Block, Glenn M Chertow, John T Sullivan, Hongjie Deng, Omar Mather, Holly Tomlin, Michael Serenko. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
PloS one.
2019; 14(3):e0213774. doi:
10.1371/journal.pone.0213774. [PMID: 30875390] - Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama, Takashi Akiba, Akifumi Fujii, Motoi Odani, Tadao Akizawa. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
Clinical therapeutics.
2018 12; 40(12):2099-2111. doi:
10.1016/j.clinthera.2018.10.016. [PMID: 30473399] - Micah Rose, Jonathan Shepherd, Petra Harris, Karen Pickett, Joanne Lord. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
PharmacoEconomics.
2018 11; 36(11):1299-1308. doi:
10.1007/s40273-018-0661-2. [PMID: 29691773] - Akira Mima, Kosuke Tansho, Dai Nagahara, Kenji Watase. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
The Journal of international medical research.
2018 Nov; 46(11):4578-4585. doi:
10.1177/0300060518786913. [PMID: 30027791] - Benjamin Wu, Murad Melhem, Raju Subramanian, Ping Chen, Bethlyn Jaramilla Sloey, Bruno Fouqueray, M Benjamin Hock, Gary L Skiles, Andrew T Chow, Edward Lee. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.
Journal of clinical pharmacology.
2018 06; 58(6):717-726. doi:
10.1002/jcph.1090. [PMID: 29534286] - Antonio Bellasi, Mario Cozzolino, Fabio Malberti, Giovanni Cancarini, Ciro Esposito, Augusto Genderini, Carlo Maria Guastoni, Patrizia Ondei, Giuseppe Pontoriero, Ugo Teatini, Giuseppe Vezzoli, Piergiorgio Messa, Francesco Locatelli. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2018 May; 35(3):. doi:
NULL. [PMID: 29786181] - Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama, Takashi Akiba, Akifumi Fujii, Motoi Odani, Tadao Akizawa. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
Clinical and experimental nephrology.
2018 Apr; 22(2):426-436. doi:
10.1007/s10157-017-1442-5. [PMID: 28836058] - Ping Chen, Adimoolam Narayanan, Benjamin Wu, Per Olsson Gisleskog, John P Gibbs, Andrew T Chow, Murad Melhem. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Clinical pharmacokinetics.
2018 01; 57(1):71-85. doi:
10.1007/s40262-017-0550-4. [PMID: 28508378] - Jianzhen Ye, Guangrui Deng, Feng Gao. Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.
Drug design, development and therapy.
2018; 12(?):901-909. doi:
10.2147/dddt.s160223. [PMID: 29719376] - Claudia Friedl, Emanuel Zitt. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Drug design, development and therapy.
2018; 12(?):1589-1598. doi:
10.2147/dddt.s134103. [PMID: 29910605] - Xiaodong Li, Longchuan Yu, Frank Asuncion, Mario Grisanti, Shawn Alexander, Kelly Hensley, Chun-Ya Han, Qing-Tian Niu, Denise Dwyer, Kelly Villasenor, Marina Stolina, Charles Dean, Michael S Ominsky, Hua Zhu Ke, James E Tomlinson, William G Richards. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Bone.
2017 Dec; 105(?):163-172. doi:
10.1016/j.bone.2017.08.026. [PMID: 28867373] - Longchuan Yu, James E Tomlinson, Shawn T Alexander, Kelly Hensley, Chun-Ya Han, Denise Dwyer, Marina Stolina, Charles Dean, William G Goodman, William G Richards, Xiaodong Li. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
Calcified tissue international.
2017 12; 101(6):641-653. doi:
10.1007/s00223-017-0319-7. [PMID: 29038882] - Masafumi Fukagawa, Keitaro Yokoyama, Takashi Shigematsu, Takashi Akiba, Akifumi Fujii, Takuto Kuramoto, Motoi Odani, Tadao Akizawa. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2017 Oct; 32(10):1723-1730. doi:
10.1093/ndt/gfw408. [PMID: 28057872] - Björn Stollenwerk, Sergio Iannazzo, Kerry Cooper, Vasily Belozeroff. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
Journal of medical economics.
2017 Oct; 20(10):1110-1115. doi:
10.1080/13696998.2017.1360309. [PMID: 28803497] - P A Ureña Torres, J Bover, M Cohen-Solal. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
Drugs of today (Barcelona, Spain : 1998).
2017 Sep; 53(9):489-500. doi:
10.1358/dot.2017.53.9.2711938. [PMID: 29238762] - Keitaro Yokoyama, Masafumi Fukagawa, Takashi Shigematsu, Takashi Akiba, Akifumi Fujii, Motoi Odani, Tadao Akizawa. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
Clinical nephrology.
2017 08; 88(2):68-78. doi:
10.5414/cn108974. [PMID: 28671062] - Raju Subramanian, Xiaochun Zhu, M Benjamin Hock, Bethlyn J Sloey, Benjamin Wu, Sarah F Wilson, Ogo Egbuna, J Greg Slatter, Jim Xiao, Gary L Skiles. Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis.
Clinical pharmacokinetics.
2017 02; 56(2):179-192. doi:
10.1007/s40262-016-0433-0. [PMID: 27517676] - Liviawati Wu, Murad Melhem, Raju Subramanian, Benjamin Wu. Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.
Journal of pharmacokinetics and pharmacodynamics.
2017 02; 44(1):43-53. doi:
10.1007/s10928-016-9503-z. [PMID: 28063122] - Geoffrey A Block, David A Bushinsky, Sunfa Cheng, John Cunningham, Bastian Dehmel, Tilman B Drueke, Markus Ketteler, Reshma Kewalramani, Kevin J Martin, Sharon M Moe, Uptal D Patel, Justin Silver, Yan Sun, Hao Wang, Glenn M Chertow. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
JAMA.
2017 01; 317(2):156-164. doi:
10.1001/jama.2016.19468. [PMID: 28097356] - Geoffrey A Block, David A Bushinsky, John Cunningham, Tilman B Drueke, Markus Ketteler, Reshma Kewalramani, Kevin J Martin, T Christian Mix, Sharon M Moe, Uptal D Patel, Justin Silver, David M Spiegel, Lulu Sterling, Liron Walsh, Glenn M Chertow. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
JAMA.
2017 01; 317(2):146-155. doi:
10.1001/jama.2016.19456. [PMID: 28097355] - Hannah A Blair. Etelcalcetide: First Global Approval.
Drugs.
2016 Dec; 76(18):1787-1792. doi:
10.1007/s40265-016-0671-3. [PMID: 27900648] - P Chen, P Olsson Gisleskog, J J Perez-Ruixo, J Xiao, J Wilkins, A Narayanan, J P Gibbs, M Melhem. Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
CPT: pharmacometrics & systems pharmacology.
2016 09; 5(9):484-94. doi:
10.1002/psp4.12106. [PMID: 27639083] - Raju Subramanian, Xiaochun Zhu, Savannah J Kerr, Joel D Esmay, Steven W Louie, Katheryne Z Edson, Sarah Walter, Michael Fitzsimmons, Mylo Wagner, Marcus Soto, Roger Pham, Sarah F Wilson, Gary L Skiles. Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).
Drug metabolism and disposition: the biological fate of chemicals.
2016 08; 44(8):1319-31. doi:
10.1124/dmd.115.068007. [PMID: 26895981] - Mark R Fielden, Charles Dean, Kurt Black, Satin G Sawant, Raju Subramanian, James E Tomlinson, Sarah Walter, Cameron Zimmermann, Mark W Griggs, Marie E McKeon, Elise M Lewis, Carol Beevers, Ian Pyrah. Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
International journal of toxicology.
2016 05; 35(3):294-308. doi:
10.1177/1091581816633407. [PMID: 26941242] - Shawn T Alexander, Thomas Hunter, Sarah Walter, Jin Dong, Derek Maclean, Amos Baruch, Raju Subramanian, James E Tomlinson. Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.
Molecular pharmacology.
2015 Nov; 88(5):853-65. doi:
10.1124/mol.115.098392. [PMID: 26290606] - Ping Chen, Murad Melhem, Jim Xiao, Mita Kuchimanchi, Juan Jose Perez Ruixo. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.
Journal of clinical pharmacology.
2015 Jun; 55(6):620-8. doi:
10.1002/jcph.460. [PMID: 25581635] - Gregory Bell, Saling Huang, Kevin J Martin, Geoffrey A Block. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients.
Current medical research and opinion.
2015 May; 31(5):943-52. doi:
10.1185/03007995.2015.1031731. [PMID: 25786369] - Jun Shen, Jim Xiao, Karen Pickthorn, Saling Huang, Gregory Bell, Andrew Vick, Ping Chen. A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects.
Journal of clinical pharmacology.
2014 Oct; 54(10):1125-33. doi:
10.1002/jcph.314. [PMID: 24752908] - Sarah Walter, Amos Baruch, Shawn T Alexander, Julie Janes, Eiketsu Sho, Jin Dong, Qun Yin, Derek Maclean, Dirk B Mendel, Felix Karim, Randolph M Johnson. Comparison of AMG 416 and cinacalcet in rodent models of uremia.
BMC nephrology.
2014 May; 15(?):81. doi:
10.1186/1471-2369-15-81. [PMID: 24884838] - Kevin J Martin, Gregory Bell, Karen Pickthorn, Saling Huang, Andrew Vick, Peter Hodsman, Munro Peacock. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2014 Feb; 29(2):385-92. doi:
10.1093/ndt/gft417. [PMID: 24235081] - Kevin J Martin, Karen Pickthorn, Saling Huang, Geoffrey A Block, Andrew Vick, Peter F Mount, David A Power, Gregory Bell. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.
Kidney international.
2014 Jan; 85(1):191-7. doi:
10.1038/ki.2013.289. [PMID: 23903371] - Sarah Walter, Amos Baruch, Jin Dong, James E Tomlinson, Shawn T Alexander, Julie Janes, Tom Hunter, Qun Yin, Derek Maclean, Gregory Bell, Dirk B Mendel, Randolph M Johnson, Felix Karim. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.
The Journal of pharmacology and experimental therapeutics.
2013 Aug; 346(2):229-40. doi:
10.1124/jpet.113.204834. [PMID: 23674604]